All In Biotech

Drug Trial Radar · NCT01951625

Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)

A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure With Reduced Ejection Fraction (HFrEF)

Last checked: Nov 20, 2026Latest source record: Mar 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 456 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

456

Actual

Start

Nov 29, 2013

Primary completion

May 14, 2015

Study completion Jun 9, 2015

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Sep 26, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Objective of the study is to find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sGC) BAY1021189 for Phase III that can be given in addition to standard therapy for heart failure with reduced ejection fraction (HFrEF).

Conditions

  • Heart Failure

Interventions

  • Vericiguat (BAY1021189) (1.25 mg)Drug

    1.25 mg BAY1021189 tablets

  • Vericiguat (BAY1021189) (5 mg)Drug

    5 mg BAY1021189 tablets

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Log-Transformed N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP) to Week 12Time frame: Baseline, Week 12

Locations

157 sites in 24 countries. Site status is shown where the registry gives one.

  • Site not named

    Fountain Valley, California

  • Site not named

    Wilmington, Delaware

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Naples, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Macon, Georgia

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Detroit, Michigan

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    Jackson, Mississippi

  • Site not named

    Buffalo, New York

  • Site not named

    Columbus, Ohio

  • Site not named

    Fairfield, Ohio

  • Site not named

    Charleston, South Carolina

  • Site not named

    Germantown, Tennessee

  • Site not named

    Nashville, Tennessee

  • Site not named

    Milwaukee, Wisconsin

  • Site not named

    Darlinghurst, New South Wales, Australia

  • Site not named

    Hobart, Tasmania, Australia

  • Site not named

    Prahran, Victoria, Australia

  • Site not named

    Salzburg, Austria

  • Site not named

    Vienna, Austria

  • Site not named

    Sankt Pölten, Lower Austria, Austria

  • Site not named

    Graz, Styria, Austria

  • Site not named

    Linz, Upper Austria, Austria

  • Site not named

    Bruges, Belgium

  • Site not named

    Bruxelles - Brussel, Belgium

  • Site not named

    Ghent, Belgium

  • Site not named

    Gilly, Belgium

  • Site not named

    Huy, Belgium

  • Site not named

    Mechelen, Belgium

  • Site not named

    Mol, Belgium

  • Site not named

    Roeselare, Belgium

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Stara Zagora, Bulgaria

  • Site not named

    Québec, Canada

Showing 40 of 157 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.